Decoy Therapeutics Inc. (DCOY) stock
DCOYNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.98−0.08 (-7.56%)
Close on Nov 13, 2026Market cap $638.94KP/E –Yield –
Decoy Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Decoy Therapeutics's ebitda for the twelve months ending Sep 30, 2026 was -$16.91M. For fiscal 2025 it was -$12.61M. The highest annual figure on record is -$1.67M in fiscal 2018.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$12.61M | – |
| FY2024 | Dec 31, 2024 | -$5.73M | – |
| FY2023 | Dec 31, 2023 | -$12.88M | – |
| FY2022 | Dec 31, 2022 | -$31.83M | – |
| FY2021 | Dec 31, 2021 | -$12.79M | – |
| FY2020 | Dec 31, 2020 | -$7.77M | – |
| FY2019 | Dec 31, 2019 | -$8.14M | – |
| FY2018 | Dec 31, 2018 | -$1.67M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$2.99M | – |
| Q2 FY2026 | Jun 30, 2026 | -$2.62M | – |
| Q1 FY2026 | Mar 31, 2026 | -$2.28M | – |
| Q4 FY2025 | Dec 31, 2025 | -$9.03M | – |
| Q3 FY2025 | Sep 30, 2025 | -$894.02K | – |
| Q2 FY2025 | Jun 30, 2025 | -$964.46K | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.72M | – |
| Q4 FY2024 | Dec 31, 2024 | -$1.49M | – |
| Q3 FY2024 | Sep 30, 2024 | -$1.01M | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.47M | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.77M | – |
| Q4 FY2023 | Dec 31, 2023 | -$969.60K | – |
| Q3 FY2023 | Sep 30, 2023 | -$2.53M | – |
| Q2 FY2023 | Jun 30, 2023 | -$3.97M | – |
| Q1 FY2023 | Mar 31, 2023 | -$5.42M | – |
| Q4 FY2022 | Dec 31, 2022 | -$6.48M | – |
| Q3 FY2022 | Sep 30, 2022 | -$14.49M | – |
| Q2 FY2022 | Jun 30, 2022 | -$4.76M | – |
| Q1 FY2022 | Mar 31, 2022 | -$6.11M | – |
| Q4 FY2021 | Dec 31, 2021 | -$4.14M | – |
| Q3 FY2021 | Sep 30, 2021 | -$3.74M | – |
| Q2 FY2021 | Jun 30, 2021 | -$3.11M | – |
| Q1 FY2021 | Mar 31, 2021 | -$1.80M | – |
| Q4 FY2020 | Dec 31, 2020 | -$1.75M | – |
| Q3 FY2020 | Sep 30, 2020 | -$1.75M | – |
| Q2 FY2020 | Jun 30, 2020 | -$1.90M | – |
| Q1 FY2020 | Mar 31, 2020 | -$2.37M | – |
| Q4 FY2019 | Dec 31, 2019 | -$2.06M | – |
| Q3 FY2019 | Sep 30, 2019 | -$3.76M | – |
| Q2 FY2019 | Jun 30, 2019 | -$907.87K | – |
| Q1 FY2019 | Mar 31, 2019 | -$1.42M | – |
| Q4 FY2018 | Dec 31, 2018 | -$2.02M | – |
See a number that looks wrong?